                                                    Concept  PeriodEnd                                                                                                                                                                                                                         Dims        Value
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:ProductMember 5.381600e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:ProductMember 5.091400e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:ProductMember 9.179300e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:RoyaltyMember 1.423000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:RoyaltyMember 1.058000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:RoyaltyMember 8.450000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                         srt:ProductOrServiceAxis:us-gaap:ProductMember; us-gaap:TypeOfArrangementAxis:us-gaap:CollaborativeArrangementMember 1.750000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                         srt:ProductOrServiceAxis:us-gaap:ProductMember; us-gaap:TypeOfArrangementAxis:us-gaap:CollaborativeArrangementMember 2.120000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                                                                         srt:ProductOrServiceAxis:us-gaap:ProductMember; us-gaap:TypeOfArrangementAxis:us-gaap:CollaborativeArrangementMember 4.370000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                         srt:ProductOrServiceAxis:us-gaap:RoyaltyMember; us-gaap:TypeOfArrangementAxis:us-gaap:CollaborativeArrangementMember 9.230000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                         srt:ProductOrServiceAxis:us-gaap:RoyaltyMember; us-gaap:TypeOfArrangementAxis:us-gaap:CollaborativeArrangementMember 6.050000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                                                                         srt:ProductOrServiceAxis:us-gaap:RoyaltyMember; us-gaap:TypeOfArrangementAxis:us-gaap:CollaborativeArrangementMember 6.140000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                            srt:ProductOrServiceAxis:pfe:PaxlovidNDALabeledUSStrategicNationalStockpileMember 4.420000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:RoyaltyMember 1.423000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:RoyaltyMember 1.058000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:RoyaltyMember 8.450000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                            srt:ProductOrServiceAxis:pfe:PaxlovidNDALabeledUSStrategicNationalStockpileMember 4.420000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                                                            srt:ProductOrServiceAxis:pfe:PaxlovidNDALabeledUSStrategicNationalStockpileMember 4.420000e+08
                                           us-gaap:Revenues 2024-12-31                                                                                                                                                                                                                              6.362700e+10
                                           us-gaap:Revenues 2023-12-31                                                                                                                                                                                                                              5.955300e+10
                                           us-gaap:Revenues 2022-12-31                                                                                                                                                                                                                              1.011750e+11
                                           us-gaap:Revenues 2024-09-29                                                                                                                                                   us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis:pfe:HaleonMember 1.425200e+10
                                           us-gaap:Revenues 2023-09-30                                                                                                                                                   us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis:pfe:HaleonMember 1.392100e+10
                                           us-gaap:Revenues 2022-09-30                                                                                                                               us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis:pfe:ConsumerHealthcareJVHaleonMember 1.356600e+10
                                           us-gaap:Revenues 2024-12-31                                                                                                                                    us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis:pfe:ViivHealthcareLimitedMember 8.971000e+09
                                           us-gaap:Revenues 2023-12-31                                                                                                                                    us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis:pfe:ViivHealthcareLimitedMember 7.845000e+09
                                           us-gaap:Revenues 2022-12-31                                                                                                                                    us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis:pfe:ViivHealthcareLimitedMember 6.955000e+09
                                           us-gaap:Revenues 2024-12-31                                                                                                                                                         us-gaap:TypeOfArrangementAxis:us-gaap:CollaborativeArrangementMember 9.486000e+09
                                           us-gaap:Revenues 2023-12-31                                                                                                                                                         us-gaap:TypeOfArrangementAxis:us-gaap:CollaborativeArrangementMember 8.400000e+09
                                           us-gaap:Revenues 2022-12-31                                                                                                                                                         us-gaap:TypeOfArrangementAxis:us-gaap:CollaborativeArrangementMember 9.588000e+09
                                           us-gaap:Revenues 2024-12-31                                                                                                 srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.240000e+10
                                           us-gaap:Revenues 2023-12-31                                                                                                 srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.823700e+10
                                           us-gaap:Revenues 2022-12-31                                                                                                 srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 9.982600e+10
                                           us-gaap:Revenues 2024-12-31                                                                                                                                                                 srt:ConsolidationItemsAxis:us-gaap:CorporateNonSegmentMember 1.228000e+09
                                           us-gaap:Revenues 2023-12-31                                                                                                                                                                 srt:ConsolidationItemsAxis:us-gaap:CorporateNonSegmentMember 1.316000e+09
                                           us-gaap:Revenues 2022-12-31                                                                                                                                                                 srt:ConsolidationItemsAxis:us-gaap:CorporateNonSegmentMember 1.349000e+09
                                           us-gaap:Revenues 2024-12-31                                                                                                                                                                                                                              6.362700e+10
                                           us-gaap:Revenues 2023-12-31                                                                                                                                                                                                                              5.955300e+10
                                           us-gaap:Revenues 2022-12-31                                                                                                                                                                                                                              1.011750e+11
                                           us-gaap:Revenues 2024-12-31                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.240000e+10
                                           us-gaap:Revenues 2023-12-31                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.823700e+10
                                           us-gaap:Revenues 2022-12-31                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 9.982600e+10
                                           us-gaap:Revenues 2024-12-31                                                              us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:ComirnatyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.353000e+09
                                           us-gaap:Revenues 2023-12-31                                                              us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:ComirnatyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.122000e+10
                                           us-gaap:Revenues 2022-12-31                                                              us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:ComirnatyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.780900e+10
                                           us-gaap:Revenues 2024-12-31                                                               us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:PaxlovidMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.716000e+09
                                           us-gaap:Revenues 2023-12-31                                                               us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:PaxlovidMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.279000e+09
                                           us-gaap:Revenues 2022-12-31                                                               us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:PaxlovidMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.893300e+10
                                           us-gaap:Revenues 2024-12-31                                          us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:ExcludingComirnatyAndPaxlovidMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.133100e+10
                                           us-gaap:Revenues 2023-12-31                                          us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:ExcludingComirnatyAndPaxlovidMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.573800e+10
                                           us-gaap:Revenues 2022-12-31                                          us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:ExcludingComirnatyAndPaxlovidMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.308400e+10
                                           us-gaap:Revenues 2024-12-31                                                                                                                                                                                     srt:StatementGeographicalAxis:country:US 3.869100e+10
                                           us-gaap:Revenues 2023-12-31                                                                                                                                                                                     srt:StatementGeographicalAxis:country:US 2.814500e+10
                                           us-gaap:Revenues 2022-12-31                                                                                                                                                                                     srt:StatementGeographicalAxis:country:US 4.331700e+10
                                           us-gaap:Revenues 2024-12-31                                                                                                                                                        srt:StatementGeographicalAxis:pfe:InternationalDevelopedMarketsMember 1.605700e+10
                                           us-gaap:Revenues 2023-12-31                                                                                                                                                        srt:StatementGeographicalAxis:pfe:InternationalDevelopedMarketsMember 2.091000e+10
                                           us-gaap:Revenues 2022-12-31                                                                                                                                                        srt:StatementGeographicalAxis:pfe:InternationalDevelopedMarketsMember 4.053400e+10
                                           us-gaap:Revenues 2024-12-31                                                                                                                                                         srt:StatementGeographicalAxis:pfe:InternationalEmergingMarketsMember 8.879000e+09
                                           us-gaap:Revenues 2023-12-31                                                                                                                                                         srt:StatementGeographicalAxis:pfe:InternationalEmergingMarketsMember 1.049800e+10
                                           us-gaap:Revenues 2022-12-31                                                                                                                                                         srt:StatementGeographicalAxis:pfe:InternationalEmergingMarketsMember 1.732400e+10
                                           us-gaap:Revenues 2024-12-31                                                                                                                                                                                                                              6.362700e+10
                                           us-gaap:Revenues 2023-12-31                                                                                                                                                                                                                              5.955300e+10
                                           us-gaap:Revenues 2022-12-31                                                                                                                                                                                                                              1.011750e+11
                                           us-gaap:Revenues 2024-12-31                                                                                                                                                                                                                              6.362700e+10
                                           us-gaap:Revenues 2023-12-31                                                                                                                                                                                                                              5.955300e+10
                                           us-gaap:Revenues 2022-12-31                                                                                                                                                                                                                              1.011750e+11
                                           us-gaap:Revenues 2024-12-31                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.240000e+10
                                           us-gaap:Revenues 2023-12-31                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.823700e+10
                                           us-gaap:Revenues 2022-12-31                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 9.982600e+10
                                           us-gaap:Revenues 2024-12-31                                                                                                            us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.013500e+10
                                           us-gaap:Revenues 2023-12-31                                                                                                            us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.079900e+10
                                           us-gaap:Revenues 2022-12-31                                                                                                            us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.318100e+10
                                           us-gaap:Revenues 2024-12-31                                                                us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:EliquisMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.366000e+09
                                           us-gaap:Revenues 2023-12-31                                                                us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:EliquisMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.747000e+09
                                           us-gaap:Revenues 2022-12-31                                                                us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:EliquisMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.480000e+09
                                           us-gaap:Revenues 2024-12-31                                                  us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:PrevnarPrevenarFamilyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.411000e+09
                                           us-gaap:Revenues 2023-12-31                                                  us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:PrevnarPrevenarFamilyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.501000e+09
                                           us-gaap:Revenues 2022-12-31                                                  us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:PrevnarPrevenarFamilyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.342000e+09
                                           us-gaap:Revenues 2024-12-31                                                               us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:PaxlovidMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.716000e+09
                                           us-gaap:Revenues 2023-12-31                                                               us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:PaxlovidMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.279000e+09
                                           us-gaap:Revenues 2022-12-31                                                               us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:PaxlovidMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.893300e+10
                                           us-gaap:Revenues 2024-12-31                                                              us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:ComirnatyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.353000e+09
                                           us-gaap:Revenues 2023-12-31                                                              us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:ComirnatyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.122000e+10
                                           us-gaap:Revenues 2022-12-31                                                              us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:ComirnatyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.780900e+10
                                           us-gaap:Revenues 2024-12-31                                                        us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:NurtecODTVyduraMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.263000e+09
                                           us-gaap:Revenues 2023-12-31                                                        us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:NurtecODTVyduraMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 9.280000e+08
                                           us-gaap:Revenues 2022-12-31                                                        us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:NurtecODTVyduraMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.130000e+08
                                           us-gaap:Revenues 2024-12-31                                                                us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:AbrysvoMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.550000e+08
                                           us-gaap:Revenues 2023-12-31                                                                us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:AbrysvoMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 8.900000e+08
                                           us-gaap:Revenues 2024-12-31                                                         us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:PremarinFamilyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.800000e+08
                                           us-gaap:Revenues 2023-12-31                                                         us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:PremarinFamilyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.970000e+08
                                           us-gaap:Revenues 2022-12-31                                                         us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:PremarinFamilyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.550000e+08
                                           us-gaap:Revenues 2024-12-31                                                                   us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:BMP2Member; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.520000e+08
                                           us-gaap:Revenues 2023-12-31                                                                   us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:BMP2Member; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.380000e+08
                                           us-gaap:Revenues 2022-12-31                                                                   us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:BMP2Member; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.770000e+08
                                           us-gaap:Revenues 2024-12-31                                                       us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:FSMEIMMUNTicoVacMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.800000e+08
                                           us-gaap:Revenues 2023-12-31                                                       us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:FSMEIMMUNTicoVacMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.680000e+08
                                           us-gaap:Revenues 2022-12-31                                                       us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:FSMEIMMUNTicoVacMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.000000e+08
                                           us-gaap:Revenues 2024-12-31                                               us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:OtherPrimaryCareProductsMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.259000e+09
                                           us-gaap:Revenues 2023-12-31                                               us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:OtherPrimaryCareProductsMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.233000e+09
                                           us-gaap:Revenues 2022-12-31                                               us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; srt:ProductOrServiceAxis:pfe:OtherPrimaryCareProductsMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.473000e+09
                                           us-gaap:Revenues 2024-12-31                                                                                                          us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.665200e+10
                                           us-gaap:Revenues 2023-12-31                                                                                                          us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.498800e+10
                                           us-gaap:Revenues 2022-12-31                                                                                                          us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.385100e+10
                                           us-gaap:Revenues 2024-12-31                                                             us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:VyndaqelMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.451000e+09
                                           us-gaap:Revenues 2023-12-31                                                             us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:VyndaqelMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.321000e+09
                                           us-gaap:Revenues 2022-12-31                                                             us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:VyndaqelMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.447000e+09
                                           us-gaap:Revenues 2024-12-31                                                              us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:XeljanzMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.168000e+09
                                           us-gaap:Revenues 2023-12-31                                                              us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:XeljanzMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.703000e+09
                                           us-gaap:Revenues 2022-12-31                                                              us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:XeljanzMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.796000e+09
                                           us-gaap:Revenues 2024-12-31                                                               us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:EnbrelMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.900000e+08
                                           us-gaap:Revenues 2023-12-31                                                               us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:EnbrelMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 8.300000e+08
                                           us-gaap:Revenues 2022-12-31                                                               us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:EnbrelMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.003000e+09
                                           us-gaap:Revenues 2024-12-31                                                           us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:SulperazonMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.370000e+08
                                           us-gaap:Revenues 2023-12-31                                                           us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:SulperazonMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.570000e+08
                                           us-gaap:Revenues 2022-12-31                                                           us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:SulperazonMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.860000e+08
                                           us-gaap:Revenues 2024-12-31                                                            us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:ZaviceftaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.860000e+08
                                           us-gaap:Revenues 2023-12-31                                                            us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:ZaviceftaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.110000e+08
                                           us-gaap:Revenues 2022-12-31                                                            us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:ZaviceftaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.120000e+08
                                           us-gaap:Revenues 2024-12-31                                                              us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:OctagamMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.090000e+08
                                           us-gaap:Revenues 2023-12-31                                                              us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:OctagamMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.450000e+08
                                           us-gaap:Revenues 2022-12-31                                                              us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:OctagamMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.860000e+08
                                           us-gaap:Revenues 2024-12-31                                                     us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:InflectraRemsimaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.090000e+08
                                           us-gaap:Revenues 2023-12-31                                                     us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:InflectraRemsimaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.900000e+08
                                           us-gaap:Revenues 2022-12-31                                                     us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:InflectraRemsimaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.320000e+08
                                           us-gaap:Revenues 2024-12-31                                                        us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:ZithromaxZmaxMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.800000e+08
                                           us-gaap:Revenues 2023-12-31                                                        us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:ZithromaxZmaxMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.060000e+08
                                           us-gaap:Revenues 2022-12-31                                                        us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:ZithromaxZmaxMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.310000e+08
                                           us-gaap:Revenues 2024-12-31                                                           us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:GenotropinMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.700000e+08
                                           us-gaap:Revenues 2023-12-31                                                           us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:GenotropinMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.390000e+08
                                           us-gaap:Revenues 2022-12-31                                                           us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:GenotropinMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.600000e+08
                                           us-gaap:Revenues 2024-12-31                                                              us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:BeneFIXMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.810000e+08
                                           us-gaap:Revenues 2023-12-31                                                              us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:BeneFIXMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.240000e+08
                                           us-gaap:Revenues 2022-12-31                                                              us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:BeneFIXMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.250000e+08
                                           us-gaap:Revenues 2024-12-31                                                              us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:CibinqoMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.150000e+08
                                           us-gaap:Revenues 2023-12-31                                                              us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:CibinqoMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.280000e+08
                                           us-gaap:Revenues 2022-12-31                                                              us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:CibinqoMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.700000e+07
                                           us-gaap:Revenues 2024-12-31                                                              us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:OxbrytaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.010000e+08
                                           us-gaap:Revenues 2023-12-31                                                              us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:OxbrytaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.280000e+08
                                           us-gaap:Revenues 2022-12-31                                                              us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:OxbrytaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.300000e+07
                                           us-gaap:Revenues 2024-12-31                                                        us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:OtherHospitalMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.448000e+09
                                           us-gaap:Revenues 2023-12-31                                                        us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:OtherHospitalMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.514000e+09
                                           us-gaap:Revenues 2022-12-31                                                        us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:OtherHospitalMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.730000e+09
                                           us-gaap:Revenues 2024-12-31                                                   us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:OtherSpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 9.070000e+08
                                           us-gaap:Revenues 2023-12-31                                                   us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:OtherSpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.920000e+08
                                           us-gaap:Revenues 2022-12-31                                                   us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:ProductOrServiceAxis:pfe:OtherSpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.430000e+08
                                           us-gaap:Revenues 2024-12-31                                                                                                               us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.561200e+10
                                           us-gaap:Revenues 2023-12-31                                                                                                               us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.245000e+10
                                           us-gaap:Revenues 2022-12-31                                                                                                               us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.279400e+10
                                           us-gaap:Revenues 2024-12-31                                                                   us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:IbranceMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.367000e+09
                                           us-gaap:Revenues 2023-12-31                                                                   us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:IbranceMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.753000e+09
                                           us-gaap:Revenues 2022-12-31                                                                   us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:IbranceMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.120000e+09
                                           us-gaap:Revenues 2024-12-31                                                                    us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:XtandiMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.039000e+09
                                           us-gaap:Revenues 2023-12-31                                                                    us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:XtandiMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.659000e+09
                                           us-gaap:Revenues 2022-12-31                                                                    us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:XtandiMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.650000e+09
                                           us-gaap:Revenues 2024-12-31                                                                    us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:PadcevMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.588000e+09
                                           us-gaap:Revenues 2023-12-31                                                                    us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:PadcevMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.300000e+07
                                           us-gaap:Revenues 2024-12-31                                                                  us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:AdcetrisMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.089000e+09
                                           us-gaap:Revenues 2023-12-31                                                                  us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:AdcetrisMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.600000e+07
                                           us-gaap:Revenues 2024-12-31                                                       us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:OncologyBiosimilarsMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.037000e+09
                                           us-gaap:Revenues 2023-12-31                                                       us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:OncologyBiosimilarsMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.407000e+09
                                           us-gaap:Revenues 2022-12-31                                                       us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:OncologyBiosimilarsMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.753000e+09
                                           us-gaap:Revenues 2024-12-31                                                                    us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:InlytaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 9.780000e+08
                                           us-gaap:Revenues 2023-12-31                                                                    us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:InlytaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.036000e+09
                                           us-gaap:Revenues 2022-12-31                                                                    us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:InlytaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.003000e+09
                                           us-gaap:Revenues 2024-12-31                                                                  us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:LorbrenaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.310000e+08
                                           us-gaap:Revenues 2023-12-31                                                                  us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:LorbrenaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.390000e+08
                                           us-gaap:Revenues 2022-12-31                                                                  us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:LorbrenaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.430000e+08
                                           us-gaap:Revenues 2024-12-31                                                                   us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:BosulifMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.450000e+08
                                           us-gaap:Revenues 2023-12-31                                                                   us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:BosulifMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.450000e+08
                                           us-gaap:Revenues 2022-12-31                                                                   us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:BosulifMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.750000e+08
                                           us-gaap:Revenues 2024-12-31                                                           us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:BraftoviMektoviMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.070000e+08
                                           us-gaap:Revenues 2023-12-31                                                           us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:BraftoviMektoviMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.770000e+08
                                           us-gaap:Revenues 2022-12-31                                                           us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:BraftoviMektoviMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.560000e+08
                                           us-gaap:Revenues 2024-12-31                                                                    us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:TukysaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.800000e+08
                                           us-gaap:Revenues 2023-12-31                                                                    us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:TukysaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.800000e+07
                                           us-gaap:Revenues 2024-12-31                                                                  us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:ElrexfioMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.330000e+08
                                           us-gaap:Revenues 2023-12-31                                                                  us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:ElrexfioMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.000000e+07
                                           us-gaap:Revenues 2024-12-31                                                                    us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:TivdakMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.310000e+08
                                           us-gaap:Revenues 2023-12-31                                                                    us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:TivdakMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.000000e+06
                                           us-gaap:Revenues 2024-12-31                                                                  us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:TalzennaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.170000e+08
                                           us-gaap:Revenues 2023-12-31                                                                  us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:TalzennaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.400000e+07
                                           us-gaap:Revenues 2022-12-31                                                                  us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:TalzennaMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.800000e+07
                                           us-gaap:Revenues 2024-12-31                                                     us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:OtherOncologyProductsMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.670000e+09
                                           us-gaap:Revenues 2023-12-31                                                     us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:OtherOncologyProductsMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.729000e+09
                                           us-gaap:Revenues 2022-12-31                                                     us-gaap:ReportingUnitAxis:pfe:OncologyMember; srt:ProductOrServiceAxis:pfe:OtherOncologyProductsMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.846000e+09
                                           us-gaap:Revenues 2024-12-31                                                                                                                                                                           srt:ProductOrServiceAxis:pfe:PfizerCentreOneMember 1.146000e+09
                                           us-gaap:Revenues 2023-12-31                                                                                                                                                                           srt:ProductOrServiceAxis:pfe:PfizerCentreOneMember 1.272000e+09
                                           us-gaap:Revenues 2022-12-31                                                                                                                                                                           srt:ProductOrServiceAxis:pfe:PfizerCentreOneMember 1.342000e+09
                                           us-gaap:Revenues 2024-12-31                                                                                                                                                                              srt:ProductOrServiceAxis:pfe:PfizerIgniteMember 8.200000e+07
                                           us-gaap:Revenues 2023-12-31                                                                                                                                                                              srt:ProductOrServiceAxis:pfe:PfizerIgniteMember 4.400000e+07
                                           us-gaap:Revenues 2022-12-31                                                                                                                                                                              srt:ProductOrServiceAxis:pfe:PfizerIgniteMember 7.000000e+06
                                           us-gaap:Revenues 2024-12-31                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.240000e+10
                                           us-gaap:Revenues 2023-12-31                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.823700e+10
                                           us-gaap:Revenues 2022-12-31                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 9.982600e+10
                                           us-gaap:Revenues 2024-12-31                                                                                                   us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember; us-gaap:SubsegmentsAxis:pfe:U.S.CommercialDivisionMember 2.676500e+10
                                           us-gaap:Revenues 2023-12-31                                                                                                   us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember; us-gaap:SubsegmentsAxis:pfe:U.S.CommercialDivisionMember 1.929900e+10
                                           us-gaap:Revenues 2022-12-31                                                                                                   us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember; us-gaap:SubsegmentsAxis:pfe:U.S.CommercialDivisionMember 3.433700e+10
                                           us-gaap:Revenues 2024-12-31                                                                                                         us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember; us-gaap:SubsegmentsAxis:pfe:OncologyDivisionMember 1.156700e+10
                                           us-gaap:Revenues 2023-12-31                                                                                                         us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember; us-gaap:SubsegmentsAxis:pfe:OncologyDivisionMember 8.450000e+09
                                           us-gaap:Revenues 2022-12-31                                                                                                         us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember; us-gaap:SubsegmentsAxis:pfe:OncologyDivisionMember 8.583000e+09
                                           us-gaap:Revenues 2024-12-31                                                                                          us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember; us-gaap:SubsegmentsAxis:pfe:InternationalCommercialDivisionMember 2.406800e+10
                                           us-gaap:Revenues 2023-12-31                                                                                          us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember; us-gaap:SubsegmentsAxis:pfe:InternationalCommercialDivisionMember 3.048800e+10
                                           us-gaap:Revenues 2022-12-31                                                                                          us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember; us-gaap:SubsegmentsAxis:pfe:InternationalCommercialDivisionMember 5.690500e+10
                                           us-gaap:Revenues 2024-12-31 us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; srt:CounterpartyNameAxis:pfe:CommercializationPartnerMember; srt:ProductOrServiceAxis:pfe:OctagamMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.290000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:ProductMember 1.392000e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:ProductMember 1.541700e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:ProductMember 3.716800e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:ProductMember 3.873100e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:RoyaltyMember 4.360000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:RoyaltyMember 3.840000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:RoyaltyMember 1.170000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:RoyaltyMember 9.920000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:RoyaltyMember 4.360000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:RoyaltyMember 3.840000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-28                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:RoyaltyMember 1.170000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                                                               srt:ProductOrServiceAxis:us-gaap:RoyaltyMember 9.920000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                            srt:ProductOrServiceAxis:pfe:PaxlovidNDALabeledUSStrategicNationalStockpileMember 4.420000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-09-29                                                                                                                                            srt:ProductOrServiceAxis:pfe:PaxlovidNDALabeledUSStrategicNationalStockpileMember 4.420000e+08
                                           us-gaap:Revenues 2025-09-28                                                                                                                                                                                                                              1.665400e+10
                                           us-gaap:Revenues 2024-09-29                                                                                                                                                                                                                              1.770200e+10
                                           us-gaap:Revenues 2025-09-28                                                                                                                                                                                                                              4.502200e+10
                                           us-gaap:Revenues 2024-09-29                                                                                                                                                                                                                              4.586400e+10
                                           us-gaap:Revenues 2025-09-28                                                                                                 srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.631000e+10
                                           us-gaap:Revenues 2024-09-29                                                                                                 srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.739200e+10
                                           us-gaap:Revenues 2025-09-28                                                                                                                                                                 srt:ConsolidationItemsAxis:us-gaap:CorporateNonSegmentMember 3.440000e+08
                                           us-gaap:Revenues 2024-09-29                                                                                                                                                                 srt:ConsolidationItemsAxis:us-gaap:CorporateNonSegmentMember 3.100000e+08
                                           us-gaap:Revenues 2025-09-28                                                                                                                                                                                                                              1.665400e+10
                                           us-gaap:Revenues 2024-09-29                                                                                                                                                                                                                              1.770200e+10
                                           us-gaap:Revenues 2025-09-28                                                                                                 srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.405600e+10
                                           us-gaap:Revenues 2024-09-29                                                                                                 srt:ConsolidationItemsAxis:us-gaap:OperatingSegmentsMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.498700e+10
                                           us-gaap:Revenues 2025-09-28                                                                                                                                                                 srt:ConsolidationItemsAxis:us-gaap:CorporateNonSegmentMember 9.660000e+08
                                           us-gaap:Revenues 2024-09-29                                                                                                                                                                 srt:ConsolidationItemsAxis:us-gaap:CorporateNonSegmentMember 8.770000e+08
                                           us-gaap:Revenues 2025-09-28                                                                                                                                                                                                                              4.502200e+10
                                           us-gaap:Revenues 2024-09-29                                                                                                                                                                                                                              4.586400e+10
                                           us-gaap:Revenues 2025-09-28                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.631000e+10
                                           us-gaap:Revenues 2024-09-29                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.739200e+10
                                           us-gaap:Revenues 2025-09-28                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.405600e+10
                                           us-gaap:Revenues 2024-09-29                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.498700e+10
                                           us-gaap:Revenues 2025-09-28                                                                                                                                                                                     srt:StatementGeographicalAxis:country:US 1.069100e+10
                                           us-gaap:Revenues 2024-09-29                                                                                                                                                                                     srt:StatementGeographicalAxis:country:US 1.206400e+10
                                           us-gaap:Revenues 2025-09-28                                                                                                                                                                                     srt:StatementGeographicalAxis:country:US 2.795900e+10
                                           us-gaap:Revenues 2024-09-29                                                                                                                                                                                     srt:StatementGeographicalAxis:country:US 2.947000e+10
                                           us-gaap:Revenues 2025-09-28                                                                                                                                                        srt:StatementGeographicalAxis:pfe:InternationalDevelopedMarketsMember 3.696000e+09
                                           us-gaap:Revenues 2024-09-29                                                                                                                                                        srt:StatementGeographicalAxis:pfe:InternationalDevelopedMarketsMember 3.412000e+09
                                           us-gaap:Revenues 2025-09-28                                                                                                                                                        srt:StatementGeographicalAxis:pfe:InternationalDevelopedMarketsMember 1.026700e+10
                                           us-gaap:Revenues 2024-09-29                                                                                                                                                        srt:StatementGeographicalAxis:pfe:InternationalDevelopedMarketsMember 9.774000e+09
                                           us-gaap:Revenues 2025-09-28                                                                                                                                                         srt:StatementGeographicalAxis:pfe:InternationalEmergingMarketsMember 2.267000e+09
                                           us-gaap:Revenues 2024-09-29                                                                                                                                                         srt:StatementGeographicalAxis:pfe:InternationalEmergingMarketsMember 2.226000e+09
                                           us-gaap:Revenues 2025-09-28                                                                                                                                                         srt:StatementGeographicalAxis:pfe:InternationalEmergingMarketsMember 6.796000e+09
                                           us-gaap:Revenues 2024-09-29                                                                                                                                                         srt:StatementGeographicalAxis:pfe:InternationalEmergingMarketsMember 6.620000e+09
                                           us-gaap:Revenues 2025-09-28                                                                                                                                                                                                                              1.665400e+10
                                           us-gaap:Revenues 2024-09-29                                                                                                                                                                                                                              1.770200e+10
                                           us-gaap:Revenues 2025-09-28                                                                                                                                                                                                                              4.502200e+10
                                           us-gaap:Revenues 2024-09-29                                                                                                                                                                                                                              4.586400e+10
                                           us-gaap:Revenues 2025-09-28                                                                                                                                                                                                                              1.665400e+10
                                           us-gaap:Revenues 2024-09-29                                                                                                                                                                                                                              1.770200e+10
                                           us-gaap:Revenues 2025-09-28                                                                                                                                                                                                                              4.502200e+10
                                           us-gaap:Revenues 2024-09-29                                                                                                                                                                                                                              4.586400e+10
                                           us-gaap:Revenues 2025-09-28                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.631000e+10
                                           us-gaap:Revenues 2024-09-29                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.739200e+10
                                           us-gaap:Revenues 2025-09-28                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.405600e+10
                                           us-gaap:Revenues 2024-09-29                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.498700e+10
                                           us-gaap:Revenues 2025-09-28                                                                                                            us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.646000e+09
                                           us-gaap:Revenues 2024-09-29                                                                                                            us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 9.060000e+09
                                           us-gaap:Revenues 2025-09-28                                                                                                            us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.888200e+10
                                           us-gaap:Revenues 2024-09-29                                                                                                            us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.122400e+10
                                           us-gaap:Revenues 2025-09-28                                                                srt:ProductOrServiceAxis:pfe:EliquisMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.015000e+09
                                           us-gaap:Revenues 2024-09-29                                                                srt:ProductOrServiceAxis:pfe:EliquisMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.617000e+09
                                           us-gaap:Revenues 2025-09-28                                                                srt:ProductOrServiceAxis:pfe:EliquisMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.941000e+09
                                           us-gaap:Revenues 2024-09-29                                                                srt:ProductOrServiceAxis:pfe:EliquisMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.534000e+09
                                           us-gaap:Revenues 2025-09-28                                                  srt:ProductOrServiceAxis:pfe:PrevnarPrevenarFamilyMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.742000e+09
                                           us-gaap:Revenues 2024-09-29                                                  srt:ProductOrServiceAxis:pfe:PrevnarPrevenarFamilyMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.803000e+09
                                           us-gaap:Revenues 2025-09-28                                                  srt:ProductOrServiceAxis:pfe:PrevnarPrevenarFamilyMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.786000e+09
                                           us-gaap:Revenues 2024-09-29                                                  srt:ProductOrServiceAxis:pfe:PrevnarPrevenarFamilyMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.853000e+09
                                           us-gaap:Revenues 2025-09-28                                                     srt:ProductOrServiceAxis:pfe:PaxlovidEUALabeledMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.225000e+09
                                           us-gaap:Revenues 2024-09-29                                                     srt:ProductOrServiceAxis:pfe:PaxlovidEUALabeledMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.703000e+09
                                           us-gaap:Revenues 2025-09-28                                                     srt:ProductOrServiceAxis:pfe:PaxlovidEUALabeledMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.144000e+09
                                           us-gaap:Revenues 2024-09-29                                                     srt:ProductOrServiceAxis:pfe:PaxlovidEUALabeledMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.989000e+09
                                           us-gaap:Revenues 2025-09-28                                                              srt:ProductOrServiceAxis:pfe:ComirnatyMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.151000e+09
                                           us-gaap:Revenues 2024-09-29                                                              srt:ProductOrServiceAxis:pfe:ComirnatyMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.422000e+09
                                           us-gaap:Revenues 2025-09-28                                                              srt:ProductOrServiceAxis:pfe:ComirnatyMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.097000e+09
                                           us-gaap:Revenues 2024-09-29                                                              srt:ProductOrServiceAxis:pfe:ComirnatyMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.970000e+09
                                           us-gaap:Revenues 2025-09-28                                                        srt:ProductOrServiceAxis:pfe:NurtecODTVyduraMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.120000e+08
                                           us-gaap:Revenues 2024-09-29                                                        srt:ProductOrServiceAxis:pfe:NurtecODTVyduraMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.370000e+08
                                           us-gaap:Revenues 2025-09-28                                                        srt:ProductOrServiceAxis:pfe:NurtecODTVyduraMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.019000e+09
                                           us-gaap:Revenues 2024-09-29                                                        srt:ProductOrServiceAxis:pfe:NurtecODTVyduraMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 8.700000e+08
                                           us-gaap:Revenues 2025-09-28                                                                srt:ProductOrServiceAxis:pfe:AbrysvoMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.790000e+08
                                           us-gaap:Revenues 2024-09-29                                                                srt:ProductOrServiceAxis:pfe:AbrysvoMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.560000e+08
                                           us-gaap:Revenues 2025-09-28                                                                srt:ProductOrServiceAxis:pfe:AbrysvoMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.530000e+08
                                           us-gaap:Revenues 2024-09-29                                                                srt:ProductOrServiceAxis:pfe:AbrysvoMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.570000e+08
                                           us-gaap:Revenues 2025-09-28                                                       srt:ProductOrServiceAxis:pfe:FSMEIMMUNTicoVacMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.000000e+08
                                           us-gaap:Revenues 2024-09-29                                                       srt:ProductOrServiceAxis:pfe:FSMEIMMUNTicoVacMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 8.100000e+07
                                           us-gaap:Revenues 2025-09-28                                                       srt:ProductOrServiceAxis:pfe:FSMEIMMUNTicoVacMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.720000e+08
                                           us-gaap:Revenues 2024-09-29                                                       srt:ProductOrServiceAxis:pfe:FSMEIMMUNTicoVacMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.460000e+08
                                           us-gaap:Revenues 2025-09-28                                               srt:ProductOrServiceAxis:pfe:OtherPrimaryCareProductsMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.210000e+08
                                           us-gaap:Revenues 2024-09-29                                               srt:ProductOrServiceAxis:pfe:OtherPrimaryCareProductsMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.420000e+08
                                           us-gaap:Revenues 2025-09-28                                               srt:ProductOrServiceAxis:pfe:OtherPrimaryCareProductsMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.071000e+09
                                           us-gaap:Revenues 2024-09-29                                               srt:ProductOrServiceAxis:pfe:OtherPrimaryCareProductsMember; us-gaap:ReportingUnitAxis:pfe:PrimaryCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.204000e+09
                                           us-gaap:Revenues 2025-09-28                                                                                                          us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.411000e+09
                                           us-gaap:Revenues 2024-09-29                                                                                                          us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.289000e+09
                                           us-gaap:Revenues 2025-09-28                                                                                                          us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.277500e+10
                                           us-gaap:Revenues 2024-09-29                                                                                                          us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.221500e+10
                                           us-gaap:Revenues 2025-09-28                                                             srt:ProductOrServiceAxis:pfe:VyndaqelMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.591000e+09
                                           us-gaap:Revenues 2024-09-29                                                             srt:ProductOrServiceAxis:pfe:VyndaqelMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.447000e+09
                                           us-gaap:Revenues 2025-09-28                                                             srt:ProductOrServiceAxis:pfe:VyndaqelMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.692000e+09
                                           us-gaap:Revenues 2024-09-29                                                             srt:ProductOrServiceAxis:pfe:VyndaqelMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.907000e+09
                                           us-gaap:Revenues 2025-09-28                                                              srt:ProductOrServiceAxis:pfe:XeljanzMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.130000e+08
                                           us-gaap:Revenues 2024-09-29                                                              srt:ProductOrServiceAxis:pfe:XeljanzMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.210000e+08
                                           us-gaap:Revenues 2025-09-28                                                              srt:ProductOrServiceAxis:pfe:XeljanzMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.630000e+08
                                           us-gaap:Revenues 2024-09-29                                                              srt:ProductOrServiceAxis:pfe:XeljanzMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 8.180000e+08
                                           us-gaap:Revenues 2025-09-28                                                           srt:ProductOrServiceAxis:pfe:SulperazonMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.540000e+08
                                           us-gaap:Revenues 2024-09-29                                                           srt:ProductOrServiceAxis:pfe:SulperazonMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.560000e+08
                                           us-gaap:Revenues 2025-09-28                                                           srt:ProductOrServiceAxis:pfe:SulperazonMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.840000e+08
                                           us-gaap:Revenues 2024-09-29                                                           srt:ProductOrServiceAxis:pfe:SulperazonMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.680000e+08
                                           us-gaap:Revenues 2025-09-28                                                            srt:ProductOrServiceAxis:pfe:InflectraMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.730000e+08
                                           us-gaap:Revenues 2024-09-29                                                            srt:ProductOrServiceAxis:pfe:InflectraMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.260000e+08
                                           us-gaap:Revenues 2025-09-28                                                            srt:ProductOrServiceAxis:pfe:InflectraMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.650000e+08
                                           us-gaap:Revenues 2024-09-29                                                            srt:ProductOrServiceAxis:pfe:InflectraMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.820000e+08
                                           us-gaap:Revenues 2025-09-28                                                            srt:ProductOrServiceAxis:pfe:ZaviceftaMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.580000e+08
                                           us-gaap:Revenues 2024-09-29                                                            srt:ProductOrServiceAxis:pfe:ZaviceftaMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.520000e+08
                                           us-gaap:Revenues 2025-09-28                                                            srt:ProductOrServiceAxis:pfe:ZaviceftaMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.570000e+08
                                           us-gaap:Revenues 2024-09-29                                                            srt:ProductOrServiceAxis:pfe:ZaviceftaMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.270000e+08
                                           us-gaap:Revenues 2025-09-28                                                               srt:ProductOrServiceAxis:pfe:EnbrelMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.540000e+08
                                           us-gaap:Revenues 2024-09-29                                                               srt:ProductOrServiceAxis:pfe:EnbrelMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.690000e+08
                                           us-gaap:Revenues 2025-09-28                                                               srt:ProductOrServiceAxis:pfe:EnbrelMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.480000e+08
                                           us-gaap:Revenues 2024-09-29                                                               srt:ProductOrServiceAxis:pfe:EnbrelMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.070000e+08
                                           us-gaap:Revenues 2025-09-28                                                           srt:ProductOrServiceAxis:pfe:GenotropinMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.280000e+08
                                           us-gaap:Revenues 2024-09-29                                                           srt:ProductOrServiceAxis:pfe:GenotropinMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.190000e+08
                                           us-gaap:Revenues 2025-09-28                                                           srt:ProductOrServiceAxis:pfe:GenotropinMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.290000e+08
                                           us-gaap:Revenues 2024-09-29                                                           srt:ProductOrServiceAxis:pfe:GenotropinMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.580000e+08
                                           us-gaap:Revenues 2025-09-28                                                              srt:ProductOrServiceAxis:pfe:OctagamMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.130000e+08
                                           us-gaap:Revenues 2024-09-29                                                              srt:ProductOrServiceAxis:pfe:OctagamMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.210000e+08
                                           us-gaap:Revenues 2025-09-28                                                              srt:ProductOrServiceAxis:pfe:OctagamMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.980000e+08
                                           us-gaap:Revenues 2024-09-29                                                              srt:ProductOrServiceAxis:pfe:OctagamMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.000000e+08
                                           us-gaap:Revenues 2025-09-28                                                        srt:ProductOrServiceAxis:pfe:ZithromaxZmaxMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.300000e+07
                                           us-gaap:Revenues 2024-09-29                                                        srt:ProductOrServiceAxis:pfe:ZithromaxZmaxMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 8.300000e+07
                                           us-gaap:Revenues 2025-09-28                                                        srt:ProductOrServiceAxis:pfe:ZithromaxZmaxMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.860000e+08
                                           us-gaap:Revenues 2024-09-29                                                        srt:ProductOrServiceAxis:pfe:ZithromaxZmaxMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.570000e+08
                                           us-gaap:Revenues 2025-09-28                                                             srt:ProductOrServiceAxis:pfe:CresembaMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 8.300000e+07
                                           us-gaap:Revenues 2024-09-29                                                             srt:ProductOrServiceAxis:pfe:CresembaMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.700000e+07
                                           us-gaap:Revenues 2025-09-28                                                             srt:ProductOrServiceAxis:pfe:CresembaMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.670000e+08
                                           us-gaap:Revenues 2024-09-29                                                             srt:ProductOrServiceAxis:pfe:CresembaMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.130000e+08
                                           us-gaap:Revenues 2025-09-28                                                              srt:ProductOrServiceAxis:pfe:CibinqoMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.900000e+07
                                           us-gaap:Revenues 2024-09-29                                                              srt:ProductOrServiceAxis:pfe:CibinqoMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.300000e+07
                                           us-gaap:Revenues 2025-09-28                                                              srt:ProductOrServiceAxis:pfe:CibinqoMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.060000e+08
                                           us-gaap:Revenues 2024-09-29                                                              srt:ProductOrServiceAxis:pfe:CibinqoMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.520000e+08
                                           us-gaap:Revenues 2025-09-28                                                        srt:ProductOrServiceAxis:pfe:OtherHospitalMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 9.850000e+08
                                           us-gaap:Revenues 2024-09-29                                                        srt:ProductOrServiceAxis:pfe:OtherHospitalMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.041000e+09
                                           us-gaap:Revenues 2025-09-28                                                        srt:ProductOrServiceAxis:pfe:OtherHospitalMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.971000e+09
                                           us-gaap:Revenues 2024-09-29                                                        srt:ProductOrServiceAxis:pfe:OtherHospitalMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.082000e+09
                                           us-gaap:Revenues 2025-09-28                                                   srt:ProductOrServiceAxis:pfe:OtherSpecialtyCareMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.070000e+08
                                           us-gaap:Revenues 2024-09-29                                                   srt:ProductOrServiceAxis:pfe:OtherSpecialtyCareMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.230000e+08
                                           us-gaap:Revenues 2025-09-28                                                   srt:ProductOrServiceAxis:pfe:OtherSpecialtyCareMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.112000e+09
                                           us-gaap:Revenues 2024-09-29                                                   srt:ProductOrServiceAxis:pfe:OtherSpecialtyCareMember; us-gaap:ReportingUnitAxis:pfe:SpecialtyCareMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.145000e+09
                                           us-gaap:Revenues 2025-09-28                                                                                                               us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.253000e+09
                                           us-gaap:Revenues 2024-09-29                                                                                                               us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.043000e+09
                                           us-gaap:Revenues 2025-09-28                                                                                                               us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.239900e+10
                                           us-gaap:Revenues 2024-09-29                                                                                                               us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.154900e+10
                                           us-gaap:Revenues 2025-09-28                                                                   srt:ProductOrServiceAxis:pfe:IbranceMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.057000e+09
                                           us-gaap:Revenues 2024-09-29                                                                   srt:ProductOrServiceAxis:pfe:IbranceMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.087000e+09
                                           us-gaap:Revenues 2025-09-28                                                                   srt:ProductOrServiceAxis:pfe:IbranceMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.083000e+09
                                           us-gaap:Revenues 2024-09-29                                                                   srt:ProductOrServiceAxis:pfe:IbranceMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.272000e+09
                                           us-gaap:Revenues 2025-09-28                                                                    srt:ProductOrServiceAxis:pfe:XtandiMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.780000e+08
                                           us-gaap:Revenues 2024-09-29                                                                    srt:ProductOrServiceAxis:pfe:XtandiMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.610000e+08
                                           us-gaap:Revenues 2025-09-28                                                                    srt:ProductOrServiceAxis:pfe:XtandiMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.602000e+09
                                           us-gaap:Revenues 2024-09-29                                                                    srt:ProductOrServiceAxis:pfe:XtandiMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.474000e+09
                                           us-gaap:Revenues 2025-09-28                                                                    srt:ProductOrServiceAxis:pfe:PadcevMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.640000e+08
                                           us-gaap:Revenues 2024-09-29                                                                    srt:ProductOrServiceAxis:pfe:PadcevMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.090000e+08
                                           us-gaap:Revenues 2025-09-28                                                                    srt:ProductOrServiceAxis:pfe:PadcevMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.432000e+09
                                           us-gaap:Revenues 2024-09-29                                                                    srt:ProductOrServiceAxis:pfe:PadcevMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.144000e+09
                                           us-gaap:Revenues 2025-09-28                                                       srt:ProductOrServiceAxis:pfe:OncologyBiosimilarsMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.150000e+08
                                           us-gaap:Revenues 2024-09-29                                                       srt:ProductOrServiceAxis:pfe:OncologyBiosimilarsMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.850000e+08
                                           us-gaap:Revenues 2025-09-28                                                       srt:ProductOrServiceAxis:pfe:OncologyBiosimilarsMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 9.320000e+08
                                           us-gaap:Revenues 2024-09-29                                                       srt:ProductOrServiceAxis:pfe:OncologyBiosimilarsMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 8.280000e+08
                                           us-gaap:Revenues 2025-09-28                                                                  srt:ProductOrServiceAxis:pfe:LorbrenaMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.680000e+08
                                           us-gaap:Revenues 2024-09-29                                                                  srt:ProductOrServiceAxis:pfe:LorbrenaMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.060000e+08
                                           us-gaap:Revenues 2025-09-28                                                                  srt:ProductOrServiceAxis:pfe:LorbrenaMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.410000e+08
                                           us-gaap:Revenues 2024-09-29                                                                  srt:ProductOrServiceAxis:pfe:LorbrenaMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.380000e+08
                                           us-gaap:Revenues 2025-09-28                                                                    srt:ProductOrServiceAxis:pfe:InlytaMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.260000e+08
                                           us-gaap:Revenues 2024-09-29                                                                    srt:ProductOrServiceAxis:pfe:InlytaMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.470000e+08
                                           us-gaap:Revenues 2025-09-28                                                                    srt:ProductOrServiceAxis:pfe:InlytaMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.880000e+08
                                           us-gaap:Revenues 2024-09-29                                                                    srt:ProductOrServiceAxis:pfe:InlytaMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.360000e+08
                                           us-gaap:Revenues 2025-09-28                                                                  srt:ProductOrServiceAxis:pfe:AdcetrisMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.150000e+08
                                           us-gaap:Revenues 2024-09-29                                                                  srt:ProductOrServiceAxis:pfe:AdcetrisMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.680000e+08
                                           us-gaap:Revenues 2025-09-28                                                                  srt:ProductOrServiceAxis:pfe:AdcetrisMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 6.870000e+08
                                           us-gaap:Revenues 2024-09-29                                                                  srt:ProductOrServiceAxis:pfe:AdcetrisMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 8.040000e+08
                                           us-gaap:Revenues 2025-09-28                                                           srt:ProductOrServiceAxis:pfe:BraftoviMektoviMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.020000e+08
                                           us-gaap:Revenues 2024-09-29                                                           srt:ProductOrServiceAxis:pfe:BraftoviMektoviMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.730000e+08
                                           us-gaap:Revenues 2025-09-28                                                           srt:ProductOrServiceAxis:pfe:BraftoviMektoviMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.190000e+08
                                           us-gaap:Revenues 2024-09-29                                                           srt:ProductOrServiceAxis:pfe:BraftoviMektoviMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.370000e+08
                                           us-gaap:Revenues 2025-09-28                                                                   srt:ProductOrServiceAxis:pfe:BosulifMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.500000e+08
                                           us-gaap:Revenues 2024-09-29                                                                   srt:ProductOrServiceAxis:pfe:BosulifMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.610000e+08
                                           us-gaap:Revenues 2025-09-28                                                                   srt:ProductOrServiceAxis:pfe:BosulifMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.500000e+08
                                           us-gaap:Revenues 2024-09-29                                                                   srt:ProductOrServiceAxis:pfe:BosulifMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.740000e+08
                                           us-gaap:Revenues 2025-09-28                                                                    srt:ProductOrServiceAxis:pfe:TukysaMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.100000e+08
                                           us-gaap:Revenues 2024-09-29                                                                    srt:ProductOrServiceAxis:pfe:TukysaMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.240000e+08
                                           us-gaap:Revenues 2025-09-28                                                                    srt:ProductOrServiceAxis:pfe:TukysaMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.440000e+08
                                           us-gaap:Revenues 2024-09-29                                                                    srt:ProductOrServiceAxis:pfe:TukysaMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.510000e+08
                                           us-gaap:Revenues 2025-09-28                                                                  srt:ProductOrServiceAxis:pfe:AromasinMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.140000e+08
                                           us-gaap:Revenues 2024-09-29                                                                  srt:ProductOrServiceAxis:pfe:AromasinMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 8.700000e+07
                                           us-gaap:Revenues 2025-09-28                                                                  srt:ProductOrServiceAxis:pfe:AromasinMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.330000e+08
                                           us-gaap:Revenues 2024-09-29                                                                  srt:ProductOrServiceAxis:pfe:AromasinMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.570000e+08
                                           us-gaap:Revenues 2025-09-28                                                                   srt:ProductOrServiceAxis:pfe:OrgovyxMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.120000e+08
                                           us-gaap:Revenues 2024-09-29                                                                   srt:ProductOrServiceAxis:pfe:OrgovyxMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 5.700000e+07
                                           us-gaap:Revenues 2025-09-28                                                                   srt:ProductOrServiceAxis:pfe:OrgovyxMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.850000e+08
                                           us-gaap:Revenues 2024-09-29                                                                   srt:ProductOrServiceAxis:pfe:OrgovyxMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.360000e+08
                                           us-gaap:Revenues 2025-09-28                                                                  srt:ProductOrServiceAxis:pfe:ElrexfioMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 8.500000e+07
                                           us-gaap:Revenues 2024-09-29                                                                  srt:ProductOrServiceAxis:pfe:ElrexfioMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.000000e+07
                                           us-gaap:Revenues 2025-09-28                                                                  srt:ProductOrServiceAxis:pfe:ElrexfioMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.300000e+08
                                           us-gaap:Revenues 2024-09-29                                                                  srt:ProductOrServiceAxis:pfe:ElrexfioMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 7.600000e+07
                                           us-gaap:Revenues 2025-09-28                                                                  srt:ProductOrServiceAxis:pfe:TalzennaMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.700000e+07
                                           us-gaap:Revenues 2024-09-29                                                                  srt:ProductOrServiceAxis:pfe:TalzennaMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.600000e+07
                                           us-gaap:Revenues 2025-09-28                                                                  srt:ProductOrServiceAxis:pfe:TalzennaMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.330000e+08
                                           us-gaap:Revenues 2024-09-29                                                                  srt:ProductOrServiceAxis:pfe:TalzennaMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 9.100000e+07
                                           us-gaap:Revenues 2025-09-28                                                                    srt:ProductOrServiceAxis:pfe:TivdakMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.700000e+07
                                           us-gaap:Revenues 2024-09-29                                                                    srt:ProductOrServiceAxis:pfe:TivdakMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 3.400000e+07
                                           us-gaap:Revenues 2025-09-28                                                                    srt:ProductOrServiceAxis:pfe:TivdakMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.150000e+08
                                           us-gaap:Revenues 2024-09-29                                                                    srt:ProductOrServiceAxis:pfe:TivdakMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 9.400000e+07
                                           us-gaap:Revenues 2025-09-28                                                     srt:ProductOrServiceAxis:pfe:OtherOncologyProductsMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.720000e+08
                                           us-gaap:Revenues 2024-09-29                                                     srt:ProductOrServiceAxis:pfe:OtherOncologyProductsMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 2.680000e+08
                                           us-gaap:Revenues 2025-09-28                                                     srt:ProductOrServiceAxis:pfe:OtherOncologyProductsMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 8.240000e+08
                                           us-gaap:Revenues 2024-09-29                                                     srt:ProductOrServiceAxis:pfe:OtherOncologyProductsMember; us-gaap:ReportingUnitAxis:pfe:OncologyMember; us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 8.370000e+08
                                           us-gaap:Revenues 2025-09-28                                                                                                                                                                           srt:ProductOrServiceAxis:pfe:PfizerCentreOneMember 3.440000e+08
                                           us-gaap:Revenues 2024-09-29                                                                                                                                                                           srt:ProductOrServiceAxis:pfe:PfizerCentreOneMember 2.850000e+08
                                           us-gaap:Revenues 2025-09-28                                                                                                                                                                           srt:ProductOrServiceAxis:pfe:PfizerCentreOneMember 9.290000e+08
                                           us-gaap:Revenues 2024-09-29                                                                                                                                                                           srt:ProductOrServiceAxis:pfe:PfizerCentreOneMember 8.200000e+08
                                           us-gaap:Revenues 2024-09-29                                                                                                                                                                              srt:ProductOrServiceAxis:pfe:PfizerIgniteMember 2.500000e+07
                                           us-gaap:Revenues 2025-09-28                                                                                                                                                                              srt:ProductOrServiceAxis:pfe:PfizerIgniteMember 3.700000e+07
                                           us-gaap:Revenues 2024-09-29                                                                                                                                                                              srt:ProductOrServiceAxis:pfe:PfizerIgniteMember 5.600000e+07
                                           us-gaap:Revenues 2025-09-28                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.631000e+10
                                           us-gaap:Revenues 2024-09-29                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 1.739200e+10
                                           us-gaap:Revenues 2025-09-28                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.405600e+10
                                           us-gaap:Revenues 2024-09-29                                                                                                                                                             us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember 4.498700e+10
                                           us-gaap:Revenues 2025-09-28                                                                                                   us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember; us-gaap:SubsegmentsAxis:pfe:U.S.CommercialDivisionMember 1.059900e+10
                                           us-gaap:Revenues 2024-09-29                                                                                                   us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember; us-gaap:SubsegmentsAxis:pfe:U.S.CommercialDivisionMember 1.196400e+10
                                           us-gaap:Revenues 2025-09-28                                                                                                   us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember; us-gaap:SubsegmentsAxis:pfe:U.S.CommercialDivisionMember 2.767700e+10
                                           us-gaap:Revenues 2024-09-29                                                                                                   us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember; us-gaap:SubsegmentsAxis:pfe:U.S.CommercialDivisionMember 2.921800e+10
                                           us-gaap:Revenues 2025-09-28                                                                                          us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember; us-gaap:SubsegmentsAxis:pfe:InternationalCommercialDivisionMember 5.711000e+09
                                           us-gaap:Revenues 2024-09-29                                                                                          us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember; us-gaap:SubsegmentsAxis:pfe:InternationalCommercialDivisionMember 5.428000e+09
                                           us-gaap:Revenues 2025-09-28                                                                                          us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember; us-gaap:SubsegmentsAxis:pfe:InternationalCommercialDivisionMember 1.637900e+10
                                           us-gaap:Revenues 2024-09-29                                                                                          us-gaap:StatementBusinessSegmentsAxis:pfe:BiopharmaSegmentMember; us-gaap:SubsegmentsAxis:pfe:InternationalCommercialDivisionMember 1.576900e+10